These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 34181499)

  • 1. Effect of renal impairment on arsenic accumulation, methylation capacity, and safety in acute promyelocytic leukemia (APL) patients treated with arsenic trioxide.
    Zhao Q; Guo M; Hostetter TH; Chen H; Lin L; Hai X
    Expert Rev Clin Pharmacol; 2021 Sep; 14(9):1173-1182. PubMed ID: 34181499
    [No Abstract]   [Full Text] [Related]  

  • 2. Influence of AS3MT polymorphisms on arsenic metabolism and liver injury in APL patients treated with arsenic trioxide.
    Lu J; Yu K; Fan S; Liu W; Dong Z; Li J; Wang X; Hai X; Zhou J
    Toxicol Appl Pharmacol; 2019 Sep; 379():114687. PubMed ID: 31330140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monomethylated arsenic was the Major methylated arsenic in Red blood cells of acute promyelocytic leukemia patients treated with arsenic trioxide.
    Guo S; Wang X; Gao C; Wu Z; Chen H; Lin L; Guo M; Gao Y; Hai X
    Toxicol Lett; 2021 Sep; 347():78-85. PubMed ID: 33865921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time course of arsenic species in red blood cells of acute promyelocytic leukemia (APL) patients treated with single agent arsenic trioxide.
    Guo M; Wang B; Liu S; Wang W; Gao C; Hu S; Fan S; Hai X; Zhou J
    Expert Rev Clin Pharmacol; 2019 Apr; 12(4):371-378. PubMed ID: 30795697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics and clinical influence factors of arsenic species in plasma and their role of arsenic species as predictors for clinical efficacy in acute promyelocytic leukemia (APL) patients treated with arsenic trioxide.
    Guo M; Zhou J; Fan S; Li L; Chen H; Lin L; Zhao Q; Wang X; Liu W; Wu Z; Hai X
    Expert Rev Clin Pharmacol; 2021 Apr; 14(4):503-512. PubMed ID: 33678104
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical pharmacokinetics and safety profile of single agent arsenic trioxide by continuous slow-rate infusion in patients with newly diagnosed acute promyelocytic leukemia.
    Gao C; Hu S; Guo M; Hai X; Zhou J
    Cancer Chemother Pharmacol; 2018 Aug; 82(2):229-236. PubMed ID: 29845392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Torsemide increases arsenic concentrations by inhibition of multidrug resistance protein 4 in arsenic trioxide treated acute promyelocytic leukemia patients.
    Lv J; Wu M; Pang C; Duan R; Zhang H; Tian S; Yang H; Hai X
    Biomed Pharmacother; 2023 Jul; 163():114858. PubMed ID: 37172335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arsenic Trioxide Therapy During Pregnancy: ATO and Its Metabolites in Maternal Blood and Amniotic Fluid of Acute Promyelocytic Leukemia Patients.
    Guo M; Lv J; Chen X; Wu M; Zhao Q; Hai X
    Front Oncol; 2022; 12():887026. PubMed ID: 35646703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymorphisms in arsenic (+ 3 oxidation state) methyltransferase (AS3MT) predict the occurrence of hyperleukocytosis and arsenic metabolism in APL patients treated with As
    Liu WS; Wang XY; Lu J; Zhang YM; Ye XM; Li JM; Zhao QL; Wu ZQ; Zhou J; Hai X
    Arch Toxicol; 2020 Apr; 94(4):1203-1213. PubMed ID: 32112223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Importance of monitoring arsenic methylation metabolism in acute promyelocytic leukemia patients receiving the treatment of arsenic trioxide.
    Zheng Y; Mao YF; Zhao HJ; Chen L; Wang LN; Zhang YX; Hu J; Li JM; Li XY; Zhu HM
    Exp Hematol Oncol; 2021 Feb; 10(1):10. PubMed ID: 33549147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of arsenic species in leukocytes and granulocytes of acute promyelocytic leukemia patients treated with arsenic trioxide.
    Wang X; Qian Z; Li H; Chen H; Lin L; Guo M; Hai X
    J Pharm Biomed Anal; 2021 Sep; 203():114201. PubMed ID: 34130006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Arsenic speciation in urine from acute promyelocytic leukemia patients undergoing arsenic trioxide treatment.
    Wang Z; Zhou J; Lu X; Gong Z; Le XC
    Chem Res Toxicol; 2004 Jan; 17(1):95-103. PubMed ID: 14727923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma protein binding of arsenic species in acute promyelocytic leukemia patients and their relationships with hepatic and renal function.
    Gao C; Duan R; Tian S; Pang C; Zhang H; Yang H; Hai X
    Expert Rev Clin Pharmacol; 2024 Nov; 17(11):1063-1069. PubMed ID: 39420768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monomethylarsonous acid binds to Cys-104α and Cys-112β of hemoglobin in acute promyelocytic leukemia patients treated with arsenic trioxide.
    Gao C; Lin L; Li J; Wu M; Lv J; Tian S; Hai X
    Toxicol Lett; 2023 May; 380():31-39. PubMed ID: 37024065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics of arsenic species in cerebrospinal fluid (CSF) of acute promyelocytic leukaemia (APL) patients treated with arsenic trioxide plus mannitol.
    Guo M; Zhao Q; Fan S; Wu Z; Lin L; Chen H; Gao Y; Hai X
    Br J Clin Pharmacol; 2021 Oct; 87(10):4020-4026. PubMed ID: 33638869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Arsenic methylation metabolism and liver injury of acute promyelocytic leukemia patients undergoing arsenic trioxide treatment.
    Wang H; Xi S; Liu Z; Yang Y; Zheng Q; Wang F; Xu Y; Wang Y; Zheng Y; Sun G
    Environ Toxicol; 2013 May; 28(5):267-75. PubMed ID: 23589229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Speciation analysis of arsenic in urine samples from APL patients treated with single agent As
    Guo M; Li J; Fan S; Liu W; Wang B; Gao C; Zhou J; Hai X
    J Pharm Biomed Anal; 2019 Jul; 171():212-217. PubMed ID: 31009876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AS3MT Polymorphisms, Arsenic Metabolism, and the Hematological and Biochemical Values in APL Patients Treated with Arsenic Trioxide.
    Lu J; Hu S; Wang W; Li J; Dong Z; Zhou J; Hai X
    Toxicol Sci; 2018 Nov; 166(1):219-227. PubMed ID: 30376134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The simpler, the better: oral arsenic for acute promyelocytic leukemia.
    Zhu HH; Hu J; Lo-Coco F; Jin J
    Blood; 2019 Aug; 134(7):597-605. PubMed ID: 31113776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pharmacokinetic and safety study of intravenous arsenic trioxide in adult cancer patients with renal impairment.
    Sweeney CJ; Takimoto C; Wood L; Porter JM; Tracewell WG; Darwish M; D'Andrea DM; Remick SC
    Cancer Chemother Pharmacol; 2010 Jul; 66(2):345-56. PubMed ID: 19911123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.